Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Inclusion Criteria: * Newly diagnosed or clinically-suspected adenocarcinoma of the head, neck, or uncinate process of the pancreas * Tumor must be surgically resectable * ECOG Performance Status of 0 to 1 * Adequate organ function as defined by study-specified laboratory tests * Must agree to use acceptable form of birth control Exclusion Criteria: * Received any type of anti-cancer treatment or immunotherapy for pancreas cancer * History of autoimmune disease (Graves or Hashimoto's disease, vitiligo, and type I diabetes are allowed) * Systemically steroid use within 14 days * Evidence of active infection * Pregnant or lactating * Diagnosed with another cancer or myeloproliferative disorder (some exceptions) * History of severe hypersensitivity reaction to any monoclonal antibody or known component of the study drugs * Known history of infection with HIV, hepatitis B, or hepatitis C * Oxygen saturation of \<92% on room air by pulse oximetry * On home oxygen